<DOC>
	<DOCNO>NCT00686010</DOCNO>
	<brief_summary>To demonstrate effect JTT-705 dose 300 mg 900 mg elevation HDL-C inhibition CETP activity versus placebo , patient present mild dyslipidaemia . These objective test 4 week treatment .</brief_summary>
	<brief_title>Efficacy Safety JTT-705 300 , 600 And 900mg Comparison With Placebo Patients With Type II Hyperlipidaemia</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Dalcetrapib</mesh_term>
	<criteria>Patients Type II hyperlipidaemia Patients lipid value indicate : HDLC &lt; 1.6 mmol/l TG &lt; 4.5 mmol/l Male females 18 65 year old ( If female must postmenopausal , premenopausal surgically sterile use acceptable form contraception ) Body Mass Index ( BMI ) &gt; 35 kg/mÂ² Pregnant , breast feeding , woman child bear potential without effective method contraception Concomitant use medication identify protocol</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>CETP Inhibitor</keyword>
	<keyword>HDL-C</keyword>
	<keyword>LDL-C</keyword>
	<keyword>Apolipoprotein</keyword>
</DOC>